L3Harris Technologies Total Cost of Revenue decreased by 73.3% to $4.34B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.8%, from $3.78B to $4.34B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 22.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.21B | $3.25B | $2.92B | $3.05B | $2.86B | $2.91B | $3.05B | $3.32B | $3.31B | $3.51B | $3.61B | $3.89B | $3.86B | $3.94B | $3.87B | $15.80B | $3.78B | $4.09B | $4.17B | $16.24B | $4.34B |
| QoQ Change | — | +1.2% | -10.2% | +4.5% | -6.3% | +1.6% | +5.0% | +8.7% | -0.3% | +6.1% | +2.9% | +7.7% | -0.6% | +2.0% | -1.7% | +308.0% | -76.1% | +8.2% | +1.8% | +289.9% | -73.3% |
| YoY Change | — | — | — | — | -11.0% | -10.6% | +4.5% | +8.6% | +15.6% | +20.6% | +18.2% | +17.2% | +16.9% | +12.4% | +7.3% | +306.5% | -2.1% | +3.9% | +7.5% | +2.8% | +14.8% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| SAS | — | — | — | — | — | — | — | $2.44B |
| CS | — | — | — | — | — | — | — | $1.16B |
| IMS | — | — | — | — | — | — | — | $807.00M |
| AR | $488.00M | $535.00M | $2.01B | $489.00M | $549.00M | $589.00M | $2.21B | — |
| Total | $3.94B | $3.87B | $15.80B | $3.78B | $4.09B | $4.17B | $16.24B | $4.34B |
AR was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.